SignalEU/UK

Novartis extends selloff as Deutsche Bank cuts on twin drug trial setbacks

Deutsche Bank downgrade and twin drug trial setbacks extend Novartis selloff.

What changed

Deutsche Bank downgrade and twin drug trial setbacks extend Novartis selloff.

Why it matters

Deutsche Bank downgrade and twin drug trial setbacks extend Novartis selloff. — impact context not separately stored; see What changed.

Sources